Top

Child's Nervous System

Published in:

01-11-2018 | Review Paper

Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors

Authors: Mohammad H. Abu Arja, Joseph R. Stanek, Jonathan L. Finlay, Mohamed S. AbdelBaki

Published in: Child's Nervous System | Issue 11/2018

Abstract

Background

The lack of a standard treatment approach has contributed to poor outcomes of patients with recurrent central nervous system (CNS) mixed malignant germ cell tumors (MMGCT). There are no data in the literature supporting optimal re-induction chemotherapy regimens that should be used for patients with recurrent CNS MMGCT.

Methods

We conducted a literature review to explore the response rate of patients with recurrent CNS MMGCT to different re-induction chemotherapy regimens by searching PubMed from 1985 through November 2017. Tumors were classified according to Japanese, European, and North American prognostic group classifications determined at initial presentation.

Results

Forty-two responses to various re-induction chemotherapy regimens reported in 38 patients were included. Two patients were inevaluable and their responses to re-induction chemotherapy were excluded. Thirty-five responses to various re-induction chemotherapy regimens were evaluable in 33 patients following a first relapse. Six (17%) responses were reported as complete or continuous complete responses, seven (20%) partial responses, two (6%) were stable disease, two (6%) were mixed responses, and 18 (51%) were progressive disease. Five of ten patients treated without platinum-based chemotherapy experienced tumor progression. There was a trend towards a higher rate of tumor progression among histological poor prognostic group patients, and among patients relapsing within 24 months of initial diagnosis; however, it was not statistically significant.

Conclusions

The histological prognostic group and time to relapse may affect the response to re-induction chemotherapy. However, further studies with larger sample size are needed to examine these associations and determine the optimal re-induction chemotherapy regimens for patients with recurrent MMGCT.

Available only for authorised users

Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-Oncology 18(suppl 5):v1–v75. https://doi.org/10.1093/neuonc/now207 CrossRefPubMed

Loius D, Ohgaki H, Wiestler O, Cavenee W, Ellison D, Figarella-Branger D, Perry A, Reifenberger G, Von Deimling A (2016) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon

Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, Seto T (1997) Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 86(3):446–455. https://doi.org/10.3171/jns.1997.86.3.0446 CrossRefPubMed

Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, Vasiljevic A, Garre ML, Ricardi U, Mann JR, Göbel U, Alapetite C, Murray MJ, Nicholson JC (2017) Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology 19(12):1661–1672. https://doi.org/10.1093/neuonc/nox122 CrossRefPubMed

Murray MJ, Bailey S, Heinemann K, Mann J, Göbel UK, Saran F, Hale JP, Calaminus G, Nicholson JC (2017) Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy. Int J Cancer 141(3):621–635. https://doi.org/10.1002/ijc.30755 CrossRefPubMed

Matsutani M, Nishikawa SY, Toshiaki K, Takashi J, Sugiyama K, Nishiyama M, Eguchi H, for the Japan CNS Germ Cell Tumor Study (2017) The second interim report of the multi-institutional prospective phase II study of radio-chemotherapy for primary intracranial germinoma in Japan. Oral presentation, fifth international CNS germ cell tumor symposium, Columbus, Ohio, June 7^th 2017. Pediatr Neurol 71:90–117CrossRef

Goldman S, Bouffet E, Fisher PG, Allen JC, Robertson PL, Chuba PJ, Donahue B, Kretschmar CS, Zhou T, Buxton AB, Pollack IF (2015) Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a children’s oncology group study. J Clin Oncol 33(22):2464–2471. https://doi.org/10.1200/JCO.2014.59.5132 CrossRefPubMedPubMedCentral

De B, Cahlon O, Dunkel IJ, De Braganca KC, Khakoo Y, Gilheeney SW, Souweidane MM, Wolden SL (2017) Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors. J Neuro-Oncol 134(2):349–356. https://doi.org/10.1007/s11060-017-2532-7 CrossRef

Wong K, Opimo AB, Olch AJ, All S, Waxer JF, Clark D, Cheng J, Chlebik A, Erdreich-Epstein A, Krieger MD, Tamrazi B, Dhall G, Finlay JL, Chang EL (2016) Re-irradiation of recurrent pineal germ cell tumors with radiosurgery: report of two cases and review of literature. Muacevic A, Adler JR, eds. Cureus 8(4):e585. https://doi.org/10.7759/cureus.585

10.

Jinguji S, Yoshimura J, Nishiyama K, Yoneoka Y, Sano M, Fukuda M, Fujii Y (2015) Long-term outcomes in patients with pineal nongerminomatous malignant germ cell tumors treated by radical resection during initial treatment combined with adjuvant therapy. Acta Neurochir 157(12):2175–2183. https://doi.org/10.1007/s00701-015-2614-2 CrossRefPubMed

11.

Nakamura H, Makino K, Kochi M, Ushio Y, Kuratsu J-I (2011) Evaluation of neoadjuvant therapy in patients with nongerminomatous malignant germ cell tumors: clinical article. J Neurosurg Pediatr 7(4):431–438. https://doi.org/10.3171/2011.1.PEDS10433 CrossRefPubMed

12.

Sonoda Y, Kumabe T, Sugiyama S, Kanamori M, Yamashita Y, Saito R, Ariga H, Takai Y, Tominaga T (2008) Germ cell tumors in the basal ganglia: problems of early diagnosis and treatment. J Neurosurg Pediatr 2(2):118–124. https://doi.org/10.3171/PED/2008/2/8/118.12 CrossRefPubMed

13.

De Giorgi U, Rosti G, Slavin S, Yaniv I, Harousseau JL, Ladenstein R, Demirer T, Dini G, European Group for Blood and Marrow Transplantation Solid Tumours and Paediatric Disease Working Parties (2005) Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer 93(4):412–417. https://doi.org/10.1038/sj.bjc.6602724 CrossRefPubMedPubMedCentral

14.

Akyüz C, Köseoğlu V, Bertan V, Söylemezoğlu F, Kutluk M, Büyükpamukçu M (1999) Primary intracranial germ cell tumors in children: a report of eight cases and review of the literature. Turk J Pediatr 41(2):161–172PubMed

15.

Sakai N, Yamada H, Andoh T, Nishimura Y, Niikawa S (1993) Long-term survival in malignant intracranial germ-cell tumors: a report of two cases and a review of the literature. Childs Nerv Syst 9(7):431–436. https://doi.org/10.1007/BF00306201 CrossRefPubMed

16.

Edwards MS, Hudgins RJ, Wilson CB, Levin VA, Wara WM (1998) Pineal region tumors in children. J Neurosurg 68(5):689–697. https://doi.org/10.3171/jns.1988.68.5.0689 CrossRef

17.

Allen JC, Bosl G, Walker R (1985) Chemotherapy trials in recurrent primary intracranialgerm cell tumors. J Neuro-Oncol 3(2):147–152. https://doi.org/10.1007/BF02228891 CrossRef

18.

Yoshida K, Toya S, Ohtani M, Okui S, Takenaka N, Harigaya K (1985) Extraneural metastasis of choriocarcinomatous element in pineal germ-cell tumor: case report. J Neurosurg 63(3):463–466. https://doi.org/10.3171/jns.1985.63.3.0463 CrossRefPubMed

19.

Baek HJ, Park HJ, Sung KW, Lee SH, Han JW, Koh KN, Im HJ, Kang HJ, Park KD (2013) Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study. J Neuro-Oncol 114(3):329–338. https://doi.org/10.1007/s11060-013-1188-1 CrossRef

20.

Da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J (2010) Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 54(3):377–383. https://doi.org/10.1002/pbc.22381 CrossRefPubMed

21.

Baranzelli MC, Patte C, Bouffet E, Portas M, Mechinaud-Lacroix F, Sariban E, Roche H, Kalifa C (1998) An attempt to treat pediatric intracranial αFP and βHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. J Neuro-Oncol 37(3):229–239. https://doi.org/10.1023/A:1005863601481 CrossRef

22.

Kobayashi T, Yoshida J, Ishiyama J, Noda S, Kito A, Kida Y (1989) Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors: an experimental and clinical study. J Neurosurg 70(5):676–681. https://doi.org/10.3171/jns.1989.70.5.0676 CrossRefPubMed

23.

Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C (1987) Carboplatin and recurrent childhood brain tumors. J Clin Oncol 5(3):459–463. https://doi.org/10.1200/JCO.1987.5.3.459 CrossRefPubMed

24.

Modak S, Gardner S, Dunkel IJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL (2004) Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 22(10):1934–1943. https://doi.org/10.1200/JCO.2004.11.053 CrossRefPubMed

25.

Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC (2015) Consensus on the management of intracranial germ-cell tumours. Lancet 16(9):e470–e477. https://doi.org/10.1016/S1470-2045(15)00244-2 CrossRefPubMed

26.

Pruitt R, DaSilva NS, Cappellano A, Belessiotis C, Diez B, Gardner S, Allen J, Weinblatt M, Gottardo N, Dhall G, Finlay JL (2015) Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiation: findings from the third international central nervous system (CNS) germ cell tumor (GCT) study. Pediatr Blood Cancer 62(11):1920–1924. https://doi.org/10.1002/pbc.25606 CrossRefPubMed

Title: Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors
Authors: Mohammad H. Abu Arja
Joseph R. Stanek
Jonathan L. Finlay
Mohamed S. AbdelBaki
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Child's Nervous System / Issue 11/2018
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-018-3940-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2018

To be or not to be Wilbrand’s knee? A question that is looking for an answer

Rare childhood hybrid histiocytosis of the central nervous system—diagnosed by stereotactic brain biopsy with marked treatment response to clofarabine

Polysomnography as an indicator for cervicomedullary decompression to treat foramen magnum stenosis in achondroplasia

Erythropoietin-mediated activation of aquaporin-4 channel for the treatment of experimental hydrocephalus

Rare congenital meningothelial hamartoma of the scalp with progressive growth

Alterations in cerebral ventricle size in children with congenital heart disease